Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Income from Continuing Operations (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Income from Continuing Operations for 3 consecutive years, with 74923000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 18.72% to 74923000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 203819000.0 through Dec 2025, up 15.64% year-over-year, with the annual reading at 203819000.0 for FY2025, 15.64% up from the prior year.
  • Income from Continuing Operations hit 74923000.0 in Q4 2025 for NewAmsterdam Pharma, down from 72005000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 16647000.0 in Q3 2024 to a low of 93767000.0 in Q1 2024.
  • Historically, Income from Continuing Operations has averaged 51860583.33 across 3 years, with a median of 44575500.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: surged 64.68% in 2024 and later tumbled 332.54% in 2025.
  • Year by year, Income from Continuing Operations stood at 49468000.0 in 2023, then crashed by 86.34% to 92177000.0 in 2024, then rose by 18.72% to 74923000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for NAMS at 74923000.0 in Q4 2025, 72005000.0 in Q3 2025, and 17364000.0 in Q2 2025.